Enhance Recovery. Optimize ICU Resource Utilization.
See how PleuraFlow® Active Clearance Technology® can help free ICU resources and get patients home faster.
–ClearFlow spokespeople cite review article as latest piece of mounting evidence pertaining to urgent need for managing retained blood after surgery– Anaheim, CA – February 1, 2018—ClearFlow Inc., a medical device company based in Anaheim, California, has announced that the cover of the January, 2018 issue of The Annals of Thoracic Surgery features a review article that elucidates the biological mechanisms by which retained shed mediastinal blood can…
–Study Supports Previously Published Data on Reduction of Postoperative Atrial Fibrillation After Heart Surgery Among Patients Treated with PleuraFlow Active Clearance Technology– Anaheim, CA – September 27, 2017—ClearFlow Inc., a medical device company based in Anaheim, California, has announced the publication of significantly positive results in a study evaluating the company’s PleuraFlow® Active Clearance Technology® System. Data from a peer-reviewed clinical study indicating a marked reduction in…
Reduction of Hospital Complications and Resource Utilization after Heart Surgery Demonstrated with Use of the PleuraFlow® ACT® System. New York City, NY – August 21, 2017 — ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that positive clinical trial results were presented at the International Coronary Congress (ICC) 2017 annual meeting on August 18th, 2017 in New York City, NY. The findings were presented…
Anaheim, CA – July 19, 2017 — ClearFlow, Inc., a medical device company based in Anaheim, California, has announced a full market release for the 20Fr SEDL version of the PleuraFlow® Active Clearance Technology® System for the treatment of pediatric cardiothoracic surgery patients. The SEDL refers to the “shorter effective drainage length”, which facilitates placement of the PleuraFlow chest tube in the smaller chests of pediatric patients. ClearFlow…
Anaheim, CA – June 20, 2017 — ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that the United States Food & Drug Administration (FDA) has granted 510[k] clearance for the company’s proprietary FlowGlide™ Active Clearance Technology® System. The FlowGlide™ System is the next generation of ClearFlow’s Active Clearance Technology that prevents or reduces chest drains from occluding with clot, which can lead to retained…
Anaheim, CA – April 18, 2017—ClearFlow Inc., a medical device company based in Anaheim, California, has received the prestigious 2017 Global Frost & Sullivan Award for New Product Innovation. The award was presented to ClearFlow for its development of the PleuraFlow® Active Clearance Technology® (ACT®) System, which has been clinically shown to reduce the occurrence of complications after cardiac surgery. Evidence suggests that chest tubes which are used for…
— ClearFlow Executives Comment on Need for New Protocols — Anaheim, CA – January 31, 2017—Clinical study results presented at the Society of Critical Care Medicine (SCCM) 46th Annual Critical Care Congress in Honolulu last week suggest that all heart surgery patients are at risk for Retained Blood Syndrome, not just high-risk patients, as previously assumed. All patients having heart surgery are required to have drainage catheters to…
ClearFlow Announces New Clinical Study with Positive Results for the PleuraFlow System Anaheim, CA – November 15, 2016. ClearFlow, Inc., a medical device company based in Anaheim, California has announced the publication of positive results in a clinical trial evaluating the PleuraFlow® Active Clearance Technology® System. Data indicating a marked reduction in Retained Blood Syndrome (RBS) among patients recovering from implantation of left ventricular assist devices (LVAD) was…